



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P & 901/3,4,5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 07/11/2022

To,
The Manager,
Department of Corporate Relationship,
BSE Limited
25th P. J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

Scrip Code: 524414

Subject: Submission of Standalone Unaudited Financial Results in compliance with Regulation 33 of SEBI (LODR) Regulations, 2015


Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

- 1) Standalone Un-audited Financial Results of the Company for the Quarter ended on 30th September, 2022.
- 2) Limited Review Report on Standalone Un-audited Financial Results for the quarter ended on 30th September, 2022.

This is for your kind information and records..

Yours faithfully,
FOR NORRIS MEDICINES LIMITED


(VIMAL D. SHAH)
MANAGING DIRECTOR
DIN No. 01506655



| General information about company | |
|--|--------------------------|
| Scrip code | 524414 |
| NSE Symbol | |
| MSEI Symbol | |
| ISIN* | INE744C01029 |
| Name of company | NORRIS MEDICINES LIMITED |
| Type of company | |
| Class of security | Equity |
| Date of start of financial year | 01-04-2022 |
| Date of end of financial year | 31-03-2023 |
| Date of board meeting when results were approved | 07-11-2022 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 01-11-2022 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Quarter | Half yearly |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited | Unaudited |
| Segment Reporting | Single segment |
| Description of single segment | Medicines |
| Start date and time of board meeting | 07-11-2022 11:00 |
| End date and time of board meeting | 07-11-2022 11:30 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Direct |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |

| Financial Results – Ind-AS | | | |
|-----------------------------------|---|--|---|
| Particulars | | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) |
| A | Date of start of reporting period | 01-07-2022 | 01-04-2022 |
| B | Date of end of reporting period | 30-09-2022 | 30-09-2022 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Part I | Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. | | |
| 1 | Income | | |
| | Revenue from operations | 302.78 | 398.09 |
| | Other income | 0 | 0 |
| | Total income | 302.78 | 398.09 |
| 2 | Expenses | | |
| (a) | Cost of materials consumed | 216.92 | 252.69 |
| (b) | Purchases of stock-in-trade | 0 | 0 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | -41.64 | -58.27 |
| (d) | Employee benefit expense | 60.38 | 104.52 |
| (e) | Finance costs | 64.8 | 74.07 |
| (f) | Depreciation, depletion and amortisation expense | 15.14 | 30.28 |
| (f) | Other Expenses | | |
| 1 | Other Expenses | 43.49 | 95.02 |
| 10 | | | |
| | Total other expenses | 43.49 | 95.02 |
| | Total expenses | 359.09 | 498.31 |

| Financial Results – Ind-AS | | | |
|-----------------------------------|---|--|---|
| Particulars | | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) |
| A | Date of start of reporting period | 01-07-2022 | 01-04-2022 |
| B | Date of end of reporting period | 30-09-2022 | 30-09-2022 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Part I | Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. | | |
| 3 | Total profit before exceptional items and tax | -56.31 | -100.22 |
| 4 | Exceptional items | 0 | 0 |
| 5 | Total profit before tax | -56.31 | -100.22 |
| 7 | Tax expense | | |
| 8 | Current tax | 0 | 0 |
| 9 | Deferred tax | 0 | 0 |
| 10 | Total tax expenses | 0 | 0 |
| 11 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0 | 0 |
| 14 | Net Profit Loss for the period from continuing operations | -56.31 | -100.22 |
| 15 | Profit (loss) from discontinued operations before tax | 0 | 0 |
| 16 | Tax expense of discontinued operations | 0 | 0 |
| 17 | Net profit (loss) from discontinued operation after tax | 0 | 0 |
| 19 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0 | 0 |
| 21 | Total profit (loss) for period | -56.31 | -100.22 |
| 22 | Other comprehensive income net of taxes | 0 | 0 |

| Financial Results – Ind-AS | | | |
|-----------------------------------|---|--|---|
| Particulars | | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) |
| A | Date of start of reporting period | 01-07-2022 | 01-04-2022 |
| B | Date of end of reporting period | 30-09-2022 | 30-09-2022 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Part I | Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. | | |
| 23 | Total Comprehensive Income for the period | -56.31 | -100.22 |
| 24 | Total profit or loss, attributable to | | |
| | Profit or loss, attributable to owners of parent | | |
| | Total profit or loss, attributable to non-controlling interests | | |
| 25 | Total Comprehensive income for the period attributable to | | |
| | Comprehensive income for the period attributable to owners of parent | 0 | 0 |
| | Total comprehensive income for the period attributable to owners of parent non-controlling interests | 0 | 0 |
| 26 | Details of equity share capital | | |
| | Paid-up equity share capital | 992.58 | 992.58 |
| | Face value of equity share capital | 0 | 0 |
| 27 | Details of debt securities | | |
| 28 | Reserves excluding revaluation reserve | | |
| 29 | Earnings per share | | |
| i | Earnings per equity share for continuing operations | | |
| | Basic earnings (loss) per share from continuing operations | -0.56 | 1 |
| | Diluted earnings (loss) per share from continuing operations | -0.56 | 1 |
| ii | Earnings per equity share for discontinued operations | | |
| | Basic earnings (loss) per share from discontinued operations | 0 | 0 |
| | Diluted earnings (loss) per share from discontinued operations | 0 | 0 |
| ii | Earnings per equity share | | |
| | Basic earnings (loss) per share from continuing and discontinued operations | -0.56 | 1 |
| | Diluted earnings (loss) per share from continuing and discontinued operations | -0.56 | 1 |
| 30 | Debt equity ratio | | |
| 31 | Debt service coverage ratio | | |
| 32 | Interest service coverage ratio | | |
| 33 | Disclosure of notes on financial results | | |

| Statement of Asset and Liabilities | |
|---|------------------------------|
| Particulars | Half year ended (dd-mm-yyyy) |
| Date of start of reporting period | 01-04-2022 |
| Date of end of reporting period | 30-09-2022 |
| Whether results are audited or unaudited | Unaudited |
| Nature of report standalone or consolidated | Standalone |
| Assets | |
| 1 | Non-current assets |
| | 676.93 |
| | |
| | |
| | 0 |
| | 0 |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | 0.94 |
| | |
| | -0.2 |
| | 39.79 |
| | 40.53 |
| | 160.85 |
| | 81.88 |
| | 960.19 |
| 2 | Current assets |
| | 294.81 |
| | |
| | |
| | 0 |
| | 154.29 |
| | 1.86 |
| | 0 |
| | 75.89 |
| | |
| | 232.04 |
| | |
| | |
| | 526.85 |

| Statement of Asset and Liabilities | |
|---|------------------------------|
| Particulars | Half year ended (dd-mm-yyyy) |
| Date of start of reporting period | 01-04-2022 |
| Date of end of reporting period | 30-09-2022 |
| Whether results are audited or unaudited | Unaudited |
| Nature of report standalone or consolidated | Standalone |
| 3 Non-current assets classified as held for sale | |
| 4 Regulatory deferral account debit balances and related deferred tax Assets | |
| Total assets | 1487.04 |
| Equity and liabilities | |
| Equity | |
| Equity attributable to owners of parent | |
| Equity share capital | 992.58 |
| Other equity | -2162.18 |
| Total equity attributable to owners of parent | -1169.6 |
| Non controlling interest | |
| Total equity | -1169.6 |
| Liabilities | |
| Non-current liabilities | |
| Non-current financial liabilities | |
| Borrowings, non-current | 1854.02 |
| Trade payables, non-current | |
| Other non-current financial liabilities | |
| Total non-current financial liabilities | 1854.02 |
| Provisions, non-current | 0 |
| Deferred tax liabilities (net) | |
| Deferred government grants, Non-current | |
| Other non-current liabilities | |
| Total non-current liabilities | 1854.02 |
| Current liabilities | |
| Current financial liabilities | |
| Borrowings, current | 296.45 |
| Trade payables, current | 192.34 |
| Other current financial liabilities | 42.28 |
| Total current financial liabilities | 531.07 |
| Other current liabilities | |
| Provisions, current | 271.55 |
| Current tax liabilities (Net) | |
| Deferred government grants, Current | |
| Total current liabilities | 802.62 |
| 3 Liabilities directly associated with assets in disposal group classified as held for sale | |
| 4 Regulatory deferral account credit balances and related deferred tax liability | |
| Total liabilities | 2656.64 |
| Total equity and liabilities | 1487.04 |
| Disclosure of notes on assets and liabilities | |

| Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results | | |
|--|---|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) |
| Date of start of reporting period | 01-07-2022 | 01-04-2022 |
| Date of end of reporting period | 30-09-2022 | 30-09-2022 |
| Whether accounts are audited or unaudited | Unaudited | Unaudited |
| Nature of report standalone or consolidated | Standalone | Standalone |
| 1 Segment Revenue (Income) | | |
| (net sale/income from each segment should be disclosed) | | |
| Total Segment Revenue | | |
| Less: Inter segment revenue | | |
| Revenue from operations | | |
| 2 Segment Result | | |
| Profit (+) / Loss (-) before tax and interest from each segment | | |
| Total Profit before tax | | |
| i. Finance cost | | |
| ii. Other Unallocable Expenditure net off Unallocable income | | |
| Profit before tax | | |
| 3 (Segment Asset - Segment Liabilities) | | |
| Segment Asset | | |
| Total Segment Asset | | |
| Un-allocable Assets | | |
| Net Segment Asset | | |
| 4 Segment Liabilities | | |
| Segment Liabilities | | |
| Total Segment Liabilities | | |
| Un-allocable Liabilities | | |
| Net Segment Liabilities | | |
| Disclosure of notes on segments | | |

| Cash flow statement,direct | | |
|-----------------------------------|---|-----------------------------|
| Particulars | | 6 months ended (dd-mm-yyyy) |
| A | Date of start of reporting period | 01-04-2022 |
| B | Date of end of reporting period | 30-09-2022 |
| C | Whether results are audited or unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone |
| Part I | Blue color marked fields are non-mandatory. | |
| | Statement of cash flows | |
| | Cash flows from used in operating activities | |
| | Classes of cash receipts from operating activities | |
| | Receipts from sales of goods and rendering of services | 0 |
| | Receipts from royalties fees, commissions and other revenue | 0 |
| | Receipts from contracts held for dealing or trading purpose | 0 |
| | Receipts from premiums and claims annuities and other policy benefits | 0 |
| | Receipts from rents and subsequent sales of assets held for rental to others and subsequently held for sale | 0 |
| | Other cash receipts from operating activities | 0 |
| | Classes of cash payments from operating activities | |
| | Payments to suppliers for goods and services | 0 |
| | Payments from contracts held for dealing or trading purpose | 0 |
| | Payments to and on behalf of employees | 0 |
| | Payments for premiums and claims, annuities and other policy benefits | 0 |
| | Payments to manufacture or acquire assets held for rental to others and subsequently held for sale | 0 |
| | Other cash payments from operating activities | 0 |
| | Net cash flows from (used in) operations | 0 |
| | Dividends received | 0 |
| | Interest paid | 0 |
| | Interest received | 0 |
| | Income taxes paid (refund) | 0 |
| | Other inflows (outflows) of cash | 0 |
| | Net cash flows from (used in) operating activities | 0 |
| | Cash flows from used in investing activities | |
| | Cash flows from losing control of subsidiaries or other businesses | 0 |
| | Cash flows used in obtaining control of subsidiaries or other businesses | 0 |
| | Other cash receipts from sales of equity or debt instruments of other entities | 0 |
| | Other cash payments to acquire equity or debt instruments of other entities | 0 |
| | Other cash receipts from sales of interests in joint ventures | 0 |
| | Other cash payments to acquire interests in joint ventures | 0 |
| | Proceeds from sales of property, plant and equipment | 0 |
| | Purchase of property, plant and equipment | 0 |
| | Proceeds from sales of investment property | 0 |
| | Purchase of investment property | 0 |
| | Proceeds from sales of goodwill | 0 |
| | Purchase of goodwill | 0 |
| | Proceeds from sales of intangible assets | 0 |

| | |
|--|----------|
| Purchase of intangible assets | 0 |
| Proceeds from biological assets other than bearer plants | 0 |
| Purchase of biological assets other than bearer plants | 0 |
| Proceeds from sales of other long-term assets | 0 |
| Purchase of other long-term assets | 0 |
| Cash advances and loans made to other parties | 0 |
| Cash receipts from repayment of advances and loans made to other parties | 0 |
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0 |
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0 |
| Dividends received | 0 |
| Interest received | 0 |
| Income taxes paid (refund) | 0 |
| Other inflows (outflows) of cash | 0 |
| Proceeds from government grants | 0 |
| Net cash flows from (used in) investing activities | 0 |
| Cash flows from used in financing activities | |
| Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control | 0 |
| Payments from changes in ownership interests in subsidiaries that do not result in loss of control | 0 |
| Proceeds from issuing shares | 0 |
| Proceeds from issuing other equity instruments | 0 |
| Payments to acquire or redeem entity's shares | 0 |
| Payments of other equity instruments | 0 |
| Proceeds from exercise of stock options | 0 |
| Proceeds from issuing debentures notes bonds etc | 0 |
| Proceeds from borrowings | 0 |
| Repayments of borrowings | 0 |
| Payments of finance lease liabilities | 0 |
| Payments of lease liabilities | 0 |
| Dividends paid | 0 |
| Interest paid | 0 |
| Income taxes paid (refund) | 0 |
| Other inflows (outflows) of cash | 0 |
| Net cash flows from (used in) financing activities | 0 |
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 0 |
| Effect of exchange rate changes on cash and cash equivalents | |
| Effect of exchange rate changes on cash and cash equivalents | 0 |
| Net increase (decrease) in cash and cash equivalents | 0 |
| Cash and cash equivalents cash flow statement at beginning of period | 0 |
| Cash and cash equivalents cash flow statement at end of period | 0 |



Limited Review Report

To
The Board of Directors
Norris Medicines Limited
Ankleshwar

We have reviewed the accompanying statement of Standalone unaudited financial results of **NORRIS MEDICINES LIMITED** ("the company") for the quarter ended **30th Sep, 2022**, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This Statement is the responsibility of the Company's Management and has been approved by the Board of directors, has been prepared in accordance with the recognition and measurement principle laid down in Indian Accounting Standards 34, "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of Companies Act 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

